Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation: AfterDmab - After Dmab

eiden University Medical Center0 个研究点目标入组 75 人开始时间: 2016年3月30日最近更新: 2022年4月19日

试验速览

暂无简介。

•Postmenopausal women with osteoporosis (T-score <-2.5) who reached a T score of >-2.5 on the LS spine and/or Fn Neck while on treatment with denosumab attending the outpatient clinic and willing to participate.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 15
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 15

•A potential subject who meets any of the following criteria will be excluded from participation in this study:
•i) secondary osteoporosis; ii) diseases that could affect bone metabolism other then osteoporosis; iii) medications that could affect bone metabolism; iv) history of any antiosteoporotic treatment other than denosumab prior to randomization.

发起方

eiden University Medical Center